Carcinogenesis involves multiple genetic and epigenetic events, yet the organizing principles underlying their choreography are poorly understood. MicroRNA (miRNA) deregulation is an important component of this landscape through both oncogenic and tumour-suppressive functions of miRNAs 1 . Of these, the highly conserved let-7 family has a prominent role in the regulation of embryonic development and maintenance of differentiated tissues and is among the most abundantly expressed miRNAs. It serves as a potent tumour suppressor via post-transcriptional repression of multiple oncogenic messenger RNA (mRNA) targets including RAS, MYC,. The let-7 family is downregulated in multiple tumour types and has been causally linked to oncogenesis 1,5-8 . Uncovering the mechanisms by which let-7 function is neutralized is therefore critical to both the fundamental understanding of cancer pathogenesis and novel therapies.
Carcinogenesis involves multiple genetic and epigenetic events, yet the organizing principles underlying their choreography are poorly understood. MicroRNA (miRNA) deregulation is an important component of this landscape through both oncogenic and tumour-suppressive functions of miRNAs 1 . Of these, the highly conserved let-7 family has a prominent role in the regulation of embryonic development and maintenance of differentiated tissues and is among the most abundantly expressed miRNAs. It serves as a potent tumour suppressor via post-transcriptional repression of multiple oncogenic messenger RNA (mRNA) targets including RAS, MYC, and HMGA2 (refs 2-4). The let-7 family is downregulated in multiple tumour types and has been causally linked to oncogenesis 1, [5] [6] [7] [8] . Uncovering the mechanisms by which let-7 function is neutralized is therefore critical to both the fundamental understanding of cancer pathogenesis and novel therapies.
Several mechanisms of let-7 disruption have emerged in different contexts. First, its biogenesis can be suppressed by the LIN28B RNAbinding protein 9 , a highly conserved heterochronic gene implicated in cancer and reported to induce tumours in multiple mouse models including hepatocellular carcinoma, colon cancer, Wilms tumour, and neuroblastoma [10] [11] [12] [13] [14] [15] [16] . Second, competing endogenous RNAs (ceRNAs) have been proposed to sponge miRNAs, including let-7, diluting their activity through competition for miRNAs with sites common to multiple ceRNA species [17] [18] [19] . Third, chromosome loss is a suggested mechanism of let-7 disruption in cancer, as genetic deletion of let-7 is associated with several solid tumours 1 .
The neuroblastoma master oncogene, MYCN, has a 910-nucleotidelong 3′ untranslated region (UTR) containing two let-7 binding sites which are almost perfectly conserved among land vertebrates, suggesting strong functional relevance [20] [21] [22] (Extended Data Fig. 1 ). Coding sequence mutations in neuroblastoma are rare 23, 24 , whereas chromosome arm gain or loss events are common 25, 26 . The most wellknown chromosomal aberration is amplification of the MYCN locus, which occurs in ~ 25% of all neuroblastomas and largely defines poor prognosis 27, 28 . Other common chromosomal deletions at chromosome arms 3p and 11q are inversely associated with MYCN amplification. The reason for this discordance is unknown.
Here we set out to understand the relationship between MYCN and let-7 in neuroblastoma. A complex relationship emerges between LIN28B activity, a novel ceRNA function of the MYCN 3′ UTR, and let-7 genetic loss, which together present a unifying model of let-7 suppression during neuroblastoma pathogenesis. This model provides an organizing principle for understanding distinct genetic patterning in neuroblastoma, with potential implications for cancer in general.
LIN28B and let-7 regulate the MYCN 3′ UTR
LIN28B is highly expressed in human neuroblastoma and its expression correlates with tumour stage, rendering the LIN28B/let-7 axis an attractive target for interrogation (Extended Data Fig. 2a-d ). Two recent reports concluded that this pathway plays a critical role in regulating MYCN and neuroblastoma cell growth 12, 13 . To examine the relationship between the MYCN transcript, let-7 and LIN28B, we first transfected non-MYCN amplified neuroblastoma cells with the MYCN open reading frame (ORF), with or without the 3′ UTR carrying intact or mutant let-7 sites (Fig. 1a) . The full-length wild-type MYCN transcript produced markedly lower MYCN protein levels than the ORFonly construct. Mutation of the let-7 sites in the 3′ UTR partly rescued MYCN expression, implicating let-7 modulation as an important component of MYCN post-transcriptional regulation ( Fig. 1b ). Expression of LIN28B suppressed the let-7 family in non-MYCN-amplified neuroblastoma cells and conferred a growth advantage. LIN28B rescued expression of the wild-type 3′ UTR construct, demonstrating that LIN28B can support MYCN expression through let-7 repression in the absence of MYCN amplification (Extended Data Fig. 2e , f and Fig. 1c ). However, when we transfected MYCN-amplified cells with a let-7a mimic, we observed decreased MYCN protein levels only above 15-and 80-fold increases in cellular levels of let-7a, respectively, Poor prognosis in neuroblastoma is associated with genetic amplification of MYCN. MYCN is itself a target of let-7, a tumour suppressor family of microRNAs implicated in numerous cancers. LIN28B, an inhibitor of let-7 biogenesis, is overexpressed in neuroblastoma and has been reported to regulate MYCN. Here we show, however, that LIN28B is dispensable in MYCN-amplified neuroblastoma cell lines, despite de-repression of let-7. We further demonstrate that MYCN messenger RNA levels in amplified disease are exceptionally high and sufficient to sponge let-7, which reconciles the dispensability of LIN28B. We found that genetic loss of let-7 is common in neuroblastoma, inversely associated with MYCN amplification, and independently associated with poor outcomes, providing a rationale for chromosomal loss patterns in neuroblastoma. We propose that let-7 disruption by LIN28B, MYCN sponging, or genetic loss is a unifying mechanism of neuroblastoma development with broad implications for cancer pathogenesis.
LIN28B is dispensable in MYCN-amplified cells
Next, we evaluated the previously reported LIN28B-let-7-MYCN regulatory circuit using published lentiviral short hairpin RNA (shRNA) constructs to knockdown LIN28B in MYCN-amplified neuroblastoma cells and observed comparable suppression of MYCN protein levels and cell growth (Extended Data Fig. 3a, b ). We further observed reduced xenograft tumour growth in cells expressing a LIN28B targeting shRNA (Extended Data Fig. 3c ). However, we did not observe an appreciable de-repression of let-7 levels upon shRNA-mediated LIN28B knockdown, which is counter to the established model (Extended Data Fig. 3d ). Moreover, we were unable to rescue these effects through overexpression of shRNA-resistant LIN28B constructs (Extended Data Fig. 3e , f). Together, these data suggest that the reported effects of the shRNAs on both cell growth and MYCN protein levels might be due to hairpin-induced toxicities.
As an alternative approach to depleting LIN28B, we tested five small interfering RNAs (siRNAs) and found that four both effectively knocked down LIN28B and, as expected, de-repressed let-7 levels (Extended Data Fig. 4a-d ). Upon extended serial siRNA transfection, we observed that despite robust LIN28B knockdown and strong derepression of let-7, MYCN protein levels were unaffected and there was no appreciable effect on cell proliferation (Extended Data Fig. 4e-g) .
To exclude the possibility of incomplete knockdown resulting in residual LIN28B activity, we employed Cas9 and four distinct guide RNAs (gRNAs) targeting LIN28B (Extended Data Fig. 4h ). We observed robust loss of LIN28B protein with all four gRNA constructs ( Fig. 2a, b ), indicating efficient disruption of the locus. We did not observe appreciable loss of MYCN protein expression or impaired cell growth, thus corroborating our siRNA-based results ( Fig. 2a-d ). In addition, the let-7 family was robustly de-repressed, consistent with the existing LIN28B/let-7 model ( Fig. 2e, f) . These observations indicate that disruption of LIN28B has little net impact on MYCN-amplified neuroblastoma cells.
Amplified MYCN mRNA is a let-7 sponge
The persistence of MYCN protein levels despite high levels of transfected let-7a or robust de-repression of let-7 upon LIN28B loss prompted us to explore novel mechanisms of let-7 perturbation. We hypothesized that there might be a ceRNA in MYCN-amplified neuroblastoma cells that serves to sponge let-7. To identify potential ceRNAs, we performed poly-A selected RNA-sequencing (mRNA-seq) on MYCN-amplified (BE(2)C and Kelly) and non-MYCN-amplified (SH-SY5Y) cells. We then determined the relative contribution of let-7 target sites provided by expressed let-7 targets. Interestingly, MYCN itself was by far the most abundant let-7 target mRNA in both BE(2)C and Kelly cells, alone providing 19.3% and 18.5% of the entire cellular let-7 target-site pool, respectively. In contrast, MYCN represented only 0.15% of the let-7 target-site pool in SH-SY5Y cells ( Fig. 3a ). In fact, MYCN mRNA was the second highest expressed mRNA in both BE(2)C and Kelly cells as opposed to the 5,409th highest in SH-SY5Y, demonstrating an exceptionally high MYCN mRNA level in MYCN-amplified cells (> 100-fold increase; Fig. 3b ). Other multiplelet-7-site mRNAs such as HMGA2, IMP1, and ARID3B were expressed at much lower levels, together suggesting that MYCN mRNA might itself be the sponge (Extended Data Fig. 5a ). This expression pattern was validated by quantitative PCR (qPCR) in a panel of additional cell lines (Extended Data Fig. 5b ).
ceRNA relationships were initially defined in part by similar expression levels between RNAs with similar 3′ UTRs 18, 29 . Two recent reports have refined this original precept, suggesting that for a given miRNA family, the miRNA:mRNA-target ratio is a major determinant of how effectively a ceRNA can impact the function of a miRNA family. At low ratios, miRNAs are sensitive to moderate levels of ceRNAs, whereas highly expressed miRNAs with high ratios are difficult to sponge, requiring very high levels of ceRNA 30, 31 . We therefore assessed total copies per cell of both MYCN mRNA and the let-7 family in BE(2)C and Kelly cells through quantified mRNA-seq and small-RNA sequencing (sRNA-seq) (Extended Data Fig. 6 ).
We calculated 13,255 and 10,615 MYCN mRNA copies per BE(2)C and Kelly cell, respectively, resulting in 26,511 and 21,231 let-7 target sites provided by MYCN ( Fig. 3c top) . In stark contrast, there were only 31 MYCN transcripts per SH-SY5Y cell. Quantification of the let-7 family in BE(2)C and Kelly cells yielded 7,259 and 1,952 total let-7 molecules per cell ( Fig. 3c bottom) , and MYCN-let-7-site:let-7 miRNA ratios of 3.65 and 10.88, respectively. These ratios satisfy the tenets of the ratio-based ceRNA model and do so as the result of a single Article reSeArcH amplified mRNA. Interestingly, let-7a was the most highly expressed let-7 family member in both cell types, accounting for over half of all let-7 molecules. These observations were confirmed by spike-in qPCR-based quantification of both MYCN and let-7 (Extended Data Fig. 7a, b ). Even upon LIN28B knockout, the MYCN-let-7-site:let-7 ratio is 1.35 in BE(2)C and 1.78 in Kelly, which remain favourable for ceRNA activity (Extended Data Fig. 7c ).
To test the capacity of MYCN mRNA to serve as a let-7 sponge, we co-transfected BE(2)C cells with a series of luciferase constructs containing the 3′ UTRs of several representative let-7 targets and control or MYCN ORF targeting siRNA (Extended Data Fig. 8a, b ). Luciferase ratios of all constructs except for empty vector controls and the let-7-site-mutated MYCN-3′ UTR were significantly reduced by either MYCN knockdown or let-7a transfection ( Fig. 3d ), suggesting that the endogenous MYCN-3′ UTR sponges steady-state levels of let-7. We then tested the sufficiency of the MYCN-3′ UTR to de-repress let-7 targets through sponging of a let-7a mimic. We co-transfected the above luciferase reporter constructs with chimaeric RFP:MYCN-3′ UTR constructs and assayed luciferase activity (Extended Data Fig. 8c, d) .
The let-7 target constructs were rescued when co-transfected with wild-type but not let-7-site-mutant MYCN-3′ UTR (Extended Data Fig. 8e ). In addition, exogenous MYCN-3′ UTR was sufficient to enhance MYCN protein expression itself in SK-N-AS cells (Extended Data Fig. 8f ).
We next tested whether endogenous let-7 targets are similarly affected. Upon MYCN knockdown, protein levels of DICER1, HK2, IMP1, and LIN28B were reduced, while neither mRNA nor let-7 levels were significantly changed (Extended Data Fig. 9a-c) . Concurrent let-7 inhibition rescued expression of the four targets, supporting posttranscriptional suppression through let-7 upon MYCN knockdown that is consistent with MYCN mRNA serving as a let-7 sponge (Extended Data Fig. 9a ). Further, these targets were not reduced at the protein level upon LIN28B knockout, which is consistent with this model (Extended Data Fig. 9d ).
Lastly, we analysed global let-7 target expression in response to depletion of the endogenous MYCN 3′ UTR. To specifically assess the role of the 3′ UTR, we transfected BE(2)C cells expressing a MYCN ORF transgene with a MYCN 3′ UTR-targeting siRNA ( Fig. 3e ). Although we did not see a global reduction of let-7 targets as a whole (Extended Data Fig. 9e ), we did observe significantly lower expression of let-7 targets with three or more total sites or more than one octamer let-7 site in their 3′ UTRs, which together define the most sensitive let-7 targets 32,33 (Fig. 3f ). Given the regulation of the MYCN 3′ UTR by multiple miRNAs 34 and unknown kinetics of how let-7 activity is restored after the removal of a ceRNA, we further challenged siCon and siMYCN cells with a modest amount of let-7a mimic, increasing cellular let-7 levels approximately eightfold (Extended Data Fig. 9f ). We then observed significantly reduced expression across all categories of let-7 targets in siMYCN cells, consistent with increased sensitivity to let-7 in the absence of the MYCN 3′ UTR ( Fig. 3g and Extended Data Fig. 9g ).
Chromosomal loss of let-7 in neuroblastoma
While neuroblastoma has a low mutation rate, chromosome arm gain and loss is frequent 23, 24 . Two of the most common chromosomal losses in neuroblastoma, chromosome arm 3p (Chr3p, ~ 33% incidence) and Chr11q (~ 45% incidence), often occur together and seldom with MYCN amplification 23,35,36 ( Fig. 4a and Extended Data Fig. 10 ). Upon analysis of Chr3p and Chr11q, we noted that the Chr3p-loss smallest region of overlap spans from 3p25. 3 within the smallest region of overlap and resulting in its loss whenever Chr3p is lost. In addition, the most common breakpoint of Chr11q immediately proximal to the let-7a2 locus, resulting in loss of let-7a2 in virtually all Chr11q deletions 35 (Fig. 4b) . Moreover, loss of Chr11q in neuroblastoma results in lower overall let-7a levels despite loss of only one of three distinct let-7a loci 38 . These observations suggest that let-7 genetic disruption may be selected for in neuroblastoma.
A model in which amplified MYCN sequesters mature let-7 would predict that selective pressure to genetically lose let-7 might be relieved in MYCN-amplified disease. Chr3p (let-7g) and Chr11q (let-7a2) loss patterns are indeed consistent with such a model. To investigate whether the extended let-7 family (Fig. 4b ) follows this loss pattern, we expanded our analysis to all eight let-7 genetic loci in 202 neuroblastomas by array comparative genomic hybridization (aCGH). We created a heat-map of copy number estimates for each miRNA locus to compare MYCN-amplified with non-amplified copy number values and observed a significant difference for six let-7 loci (Fig. 5a, b top) . At least one let-7 family member was lost in 63.4% of non-amplified tumours and in only 16.7% of amplified ( Fig. 5b top) , resulting in average let-7 copy number changes of − 1.94 and − 0.36 per tumour, respectively (Fig. 5b bottom) . This pattern of copy number loss for let-7 is distinct from the unrelated miR-103a family (Fig. 5b ), suggesting that the let-7 pattern is not reflective of general chromosomal patterning.
The most commonly lost were let-7a2, let-7f2, and let-7g, whereas let-7a3/7b and let-7i were not significantly lost in any tumour subset. We reasoned that loss frequency might relate to initial expression level. To interrogate this possibility, we used publicly available sRNA-seq data to examine the relative expression levels of mature let-7 in 12 distinct primary and tumour cell lines that have intact let-7 loci (Extended Data Fig. 10b ). We observed that let-7a, let-7f, and let-7g are present at higher relative levels than other let-7 family members, which mirrors the copy number loss patterns in non-MYCN-amplified neuroblastoma (Fig. 5c ). MiR-100, the miRNA-cluster partner of let-7a2, is more highly expressed than most let-7s and their cluster partners, suggesting that Article reSeArcH the bulk of the let-7a reads may come from the let-7a2/miR-100 locus (Fig. 5c) .
A limitation of sRNA-seq is that it cannot distinguish between loci that produce the same mature miRNA. Family members of let-7 are coordinately transcribed as part of larger host transcripts from which they are then processed, which allows for locus-specific expression analysis 7, 39, 40 (Extended Data Fig. 10c ). We therefore analysed relative expression levels of let-7 host transcripts in six primary and tumour cell lines. Host transcript levels for let-7a2, let-7f2, and let-7g were significantly higher than for other let-7 host transcripts (Extended Data Fig. 10d and Fig. 5d ), reflecting the pattern of most frequent locus loss in non-amplified disease. In addition, analysis of existing human neuroblastoma mRNA-seq and microarray data sets revealed lower expression of the let-7a2, let-7f2, and let-7g host transcripts in nonamplified compared with MYCN-amplified tumours, which is consistent with observed patterns of copy number loss in our aCGH data set ( Fig. 5e and Extended Data Fig. 10e ). Further, MYCN and let-7 expression are negatively correlated in non-amplified disease, underscoring the importance of let-7 disruption in the absence of the MYCN ceRNA 34 . These data may collectively explain both preferential loss of certain let-7 loci and common patterns of chromosomal loss in neuroblastoma.
Further emphasizing the significance of let-7 suppression is the observation that non-MYCN-amplified neuroblastoma patients had significantly worse overall survival if there was a let-7 copy number loss event (Fig. 5f top) . In the rare case where MYCN amplification and let-7 copy number loss occurred together, overall survival was dramatically reduced relative to the already-poor prognosis of MYCN amplification (Fig. 5f bottom) , suggesting a deleterious synergy between two powerful but typically exclusive mechanisms of functional let-7 disruption.
Of note, one of the tumours in the aCGH data set had genetic amplification of LIN28B (copy number = 23; Fig. 5a ). This tumour patterned closely with MYCN-amplified tumours with regard to net let-7 loss and tumour stage (IV) despite being 2n for MYCN. This may represent a case where LIN28B significantly contributed to neuroblastoma through let-7 suppression, similar to the reported mouse model of murine-Lin28b driven neuroblastoma 12 .
Discussion
The known functionality of LIN28B, together with the patterns of genetic deletion of let-7 and amplified MYCN ceRNA (aceRNA) activity described here, establish that neuroblastoma employs multiple mechanisms to neutralize let-7, placing let-7 disruption at the centre of neuroblastoma pathogenesis. We thus propose that let-7 biogenesis and function are targeted in neuroblastoma by several disparate mechanisms: high frequency genetic loss, LIN28B activity, or MYCN aceRNA (Extended Data Fig. 10f ). This model has implications for our understanding of neuroblastoma pathogenesis, disease modelling, and the rational design of therapeutic strategies, and may represent a more general feature of human cancer. First, our model offers a plausible explanation for the uniquely high MYCN mRNA levels in amplified neuroblastoma, which enable both robust expression of MYCN protein and adequate copies of a ceRNA sufficient to impair the function of a highly expressed miRNA such as let-7. Questions may remain about whether an observed > 100-fold increase in MYCN mRNA, which increases the total let-7 target sites across the cellular pool of mRNAs by only approximately 25%, is sufficient to mediate a ceRNA effect on let-7. However, our functional data based on loss of the MYCN 3′ UTR, including candidate reporter analysis of let-7-site-containing 3′ UTRs and global let-7-target mRNAseq analysis ( Fig. 3d-g) , suggest that MYCN mRNA may be a preferred target that in abundance can sequester and impair let-7. Further, in tumours lacking MYCN amplification, our model suggests that selective pressure to disrupt let-7 explains the well-known, yet unresolved, patterns of MYCN-amplification-independent chromosome 3p and 11q loss. AceRNA function of MYCN mRNA also accounts for the dispensability of LIN28B in MYCN-amplified cell lines, suggesting that LIN28B may serve a redundant let-7 suppressive role.
Our findings suggest that highly expressed 3′ UTRs contribute to miRNA deregulation in cancer, and therefore both coding and non-coding functions of oncogenic mRNAs should be considered in animal tumour modelling. For example, both the TH-MYCN and LSL-MYCN;Dbh-iCre models of murine neuroblastoma overexpress the MYCN ORF and lack 3′ UTRs. Notably, the TH-MYCN model has similar patterns of let-7a2, let-7f2, and let-7g genetic loss as nonamplified human disease and both models broadly downregulate the let-7 family 34, 41 , further suggesting that let-7 disruption is important even in the presence of MYCN protein expression. Moreover, a recent report demonstrates that high-level expression of the BRAF pseudogene, which contains a functional 3′ UTR but does not encode a protein, is sufficient to induce lymphoma in mice 42 . Consequently, full-length mRNA transgenes may yield more accurate genetic modelling of human tumours in animals.
Lastly, our model establishes let-7 restoration as a key therapeutic goal in neuroblastoma. There are few neuroblastoma-specific therapies, and attempts to directly target MYCN have met with little success, despite efforts spanning the past 20 years (refs 25, 26, 43) . The fact that MYCN mRNA has such a strong functional connection to let-7 exposes a valuable opportunity to target MYCN itself and provides hope of delivering disease-specific therapy to the worst prognostic class of neuroblastoma.
We show here that disparate modes of let-7 suppression are selectively and inversely related in neuroblastoma. Given that both oncogenic amplification and disruption of let-7 biogenesis appear to play central roles in multiple cancer types 15, [44] [45] [46] [47] , our model may provide a novel organizing principle by which to consider and interrogate genetic events in a broad range of tumours.
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Extended Data Figure 3 | Short hairpin knockdown of LIN28B in neuroblastoma. a, Immunoblot for indicated proteins MYCN and LIN28B in MYCN-amplified cells infected with LIN28B targeting lentiviral shRNAs. For gel source data, see Supplementary Figures . b, Cell proliferation analysis of cells described in a (n = 3 independent experiments). c, Average tumour size of human-mouse subcutaneous xenograft tumour analysis 3 weeks after injection of 2 × 10 6 cells infected with a LIN28B targeting lentiviral shRNA (n = 6 mice for BE(2)C, n = 3 mice for SK-N-DZ; Supplementary Figures and Source Data (ED Fig 3) ). d, qPCR analysis of let-7a, let-7b, and let-7i levels in cells described in a (mean plus s.e.m. of three independent experiments shown). e, Cell proliferation analysis of BE(2)C cells stably expressing red fluorescence protein (RFP), Flag-tagged LIN28B ORF, or shRNA resistant Flag-tagged LIN28B (LIN28B shRes) infected with LIN28B lentiviral shRNAs targeting the LIN28B 3′ UTR (ShL28B-UTR) or the LIN28B open-reading frame (ShL28B-ORF). Cell counts were performed 7 days after lentiviral shRNA infection (mean plus s.e.m. of three independent experiments shown). f, Immunoblot for indicated proteins in cells described in e. For gel source data, see Supplementary Figures. 
